/RXST
RXST Stock - RxSight, Inc.
Healthcare|Medical - DevicesNASDAQ
$12.03-2.27%
$0.28 (-2.27%) • Dec 19
45
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.59
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).16
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.75
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-16.9%upside
Target: $10.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RXST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.91 – $12.15
TARGET (TP)$10.00
STOP LOSS$11.07
RISK/REWARD1:-2.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.13
52W High$37.13
52W Low$6.32
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $139.93M | $89.08M | $49.01M | $22.59M | $14.68M |
| Gross Profit | $98.94M | $53.77M | $21.33M | $4.52M | $1.71M |
| Gross Margin | 70.7% | 60.4% | 43.5% | 20.0% | 11.6% |
| Operating Income | $-36,858,000 | $-50,085,000 | $-63,318,000 | $-52,787,000 | $-35,405,000 |
| Net Income | $-27,455,000 | $-48,608,000 | $-66,756,000 | $-48,688,000 | $27.57M |
| Net Margin | -19.6% | -54.6% | -136.2% | -215.5% | 187.9% |
| EPS | $-0.71 | $-1.41 | $-2.41 | $-1.78 | $0.18 |
Company Overview
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
44%
Hold / Neutral
9
50%
Sell / Underperform
1
6%
Analyst Consensus🔴 Bearish
8 Bullish10 Neutral/Bearish
Price Targets
$33
Average Target
↑ 175.5% Upside
Now
$9
Low
$33
Average
$72
High
Based on 21 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 15th 2025 | Morgan Stanley | Downgrade | Equal Weight | $9 |
| July 10th 2025 | Jefferies | Downgrade | Hold | $9 |
| July 9th 2025 | Oppenheimer | Downgrade | Perform | - |
| July 9th 2025 | Wells Fargo | Downgrade | Equal Weight | $9 |
| July 9th 2025 | BTIG Research | Downgrade | Neutral | - |
| May 19th 2025 | Wells Fargo | Upgrade | Overweight | $25 |
| April 15th 2025 | Piper Sandler | Initiation | Neutral | $18 |
| April 9th 2025 | UBS | Downgrade | Neutral | $16 |
| April 4th 2025 | JP Morgan | Downgrade | Underweight | $17← $40 |
| April 3rd 2025 | BofA Securities | Downgrade | Underperform | $22← $36 |
| December 20th 2024 | Stifel | Downgrade | Hold | $40← $65 |
| December 11th 2024 | Wells Fargo | Downgrade | Equal Weight | $42← $56 |
| December 6th 2024 | UBS | Initiation | Buy | $52 |
| October 29th 2024 | Jefferies | Initiation | Buy | $72 |
| August 20th 2024 | Needham | Reiterated | Buy | $66← $54 |
Earnings History & Surprises
RXSTBeat Rate
83%
Last 18 quarters
Avg Surprise
-4.1%
EPS vs Estimate
Beats / Misses
15/3
Last 12 quarters
Latest EPS
$-0.04
Q4 2025
EPS Surprise History
Q1 24
+27.8%
$-0.26vs$-0.36
Q2 24
+29.4%
$-0.12vs$-0.17
Q3 24
+27.3%
$-0.16vs$-0.22
Q4 24
+36.0%
$-0.16vs$-0.25
Q1 25
-70.0%
$0.03vs$0.10
Q2 25
+25.0%
$-0.03vs$-0.04
Q3 25
+20.0%
$-0.08vs$-0.10
Q4 25
+78.9%
$-0.04vs$-0.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 24, 2026 | $-0.25 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.19 | $-0.04 | +78.9% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.10 | $-0.08 | +20.0% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.04 | $-0.03 | +25.0% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $0.10 | $0.03 | -70.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.25 | $-0.16 | +36.0% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $-0.22 | $-0.16 | +27.3% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $-0.17 | $-0.12 | +29.4% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.36 | $-0.26 | +27.8% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.42 | $-0.35 | +16.7% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.47 | $-0.40 | +14.9% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.52 | $-0.42 | +19.2% | ✓ BEAT |
Q1 2023 | Mar 6, 2023 | $-0.72 | $-0.56 | +22.2% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.70 | $-0.61 | +12.9% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.68 | $-0.50 | +26.5% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.56 | $-0.54 | +3.6% | ✓ BEAT |
Q1 2022 | Mar 8, 2022 | $-0.58 | $-0.47 | +19.0% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.61 | $-0.65 | -6.6% | ✗ MISS |
Q3 2021 | Sep 9, 2021 | $-0.68 | $-3.24 | -376.5% | ✗ MISS |
Q3 2021 | Jul 30, 2021 | — | $-0.36 | — | — |
Latest News
Morgan Stanley Maintains Equal-Weight on RxSight, Raises Price Target to $10
➖ NeutralBenzinga•Dec 2, 2025, 05:53 PM
JP Morgan Maintains Underweight on RxSight, Raises Price Target to $9
➖ NeutralBenzinga•Nov 6, 2025, 10:03 PM
Wells Fargo Maintains Equal-Weight on RxSight, Raises Price Target to $10
➖ NeutralBenzinga•Nov 6, 2025, 03:43 PM
RxSight shares are trading higher after the company raised its full-year sales guidance.
📈 PositiveBenzinga•Nov 6, 2025, 11:23 AM
Needham Maintains Buy on RxSight, Raises Price Target to $12
📈 PositiveBenzinga•Nov 6, 2025, 10:12 AM
RxSight shares are trading higher after the company raised its full-year sales guidance.
📈 PositiveBenzinga•Nov 5, 2025, 10:23 PM
RxSight Raises FY2025 Sales Guidance from $120.000M-$130.000M to $125.000M-$130.000M vs $125.489M Est
📈 PositiveBenzinga•Nov 5, 2025, 09:20 PM
RxSight Q3 Adj. EPS $(0.04) Beats $(0.38) Estimate, Sales $30.300M Beat $25.278M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 09:19 PM
RxSight stock falls after Wells, BTIG downgrade on poor results
📉 NegativeSeeking Alpha•Jul 9, 2025, 02:20 PM
RxSight stock slides on lower Q2 revenue guidance
📉 NegativeSeeking Alpha•Jul 8, 2025, 08:40 PM
Frequently Asked Questions about RXST
What is RXST's current stock price?
RxSight, Inc. (RXST) is currently trading at $12.03 per share. The stock has moved -2.27% today.
What is the analyst price target for RXST?
The average analyst price target for RXST is $10.00, based on 1 analyst.
What sector is RxSight, Inc. in?
RxSight, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is RXST's market cap?
RxSight, Inc. has a market capitalization of $0.49 billion, making it a small-cap company.
Does RXST pay dividends?
No, RxSight, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBFLY
Butterfly Network, Inc.
$3.56
Mkt Cap: $0.9B
CERS
Cerus Corporation
$2.09
Mkt Cap: $0.4B
DCTH
Delcath Systems, Inc.
$10.06
Mkt Cap: $0.3B
DMAC
DiaMedica Therapeutics Inc.
$8.48
Mkt Cap: $0.4B
KIDS
OrthoPediatrics Corp.
$17.07
Mkt Cap: $0.4B
NPCE
NeuroPace, Inc.
$16.59
Mkt Cap: $0.6B
SMLR
Semler Scientific, Inc.
$17.93
Mkt Cap: $0.3B
SRDX
Surmodics, Inc.
$42.98
Mkt Cap: $0.6B
TCMD
Tactile Systems Technology, Inc.
$28.92
Mkt Cap: $0.6B
TMCI
Treace Medical Concepts, Inc.
$2.57
Mkt Cap: $0.2B
Explore stocks similar to RXST for comparison